仅仅相隔一周，国内两大“首仿收割机”接连扣动了扳机。就在几天前的 1 月 16 日，CDE的承办栏里跳出了一条重磅信息：石药集团欧意药业正式递交了依达拉奉右莰醇注射用浓溶液的仿制药上市申请（注册分类 4 类）。而这并非孤立事件——把日历往前翻一周，1 月 9 日，四川科伦药业的相关申请也已赫然在列。如果再算上此前早已布局的江苏联环药业、海南合瑞制药等企业，一场针对国产脑卒中“超级大单品”——...
Source Link仅仅相隔一周，国内两大“首仿收割机”接连扣动了扳机。就在几天前的 1 月 16 日，CDE的承办栏里跳出了一条重磅信息：石药集团欧意药业正式递交了依达拉奉右莰醇注射用浓溶液的仿制药上市申请（注册分类 4 类）。而这并非孤立事件——把日历往前翻一周，1 月 9 日，四川科伦药业的相关申请也已赫然在列。如果再算上此前早已布局的江苏联环药业、海南合瑞制药等企业，一场针对国产脑卒中“超级大单品”——...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.